🔗 Share this article

Chancellor Reeves has announced she is planning "focused measures to deal with cost of living challenges" in the upcoming financial statement.

During an interview with the BBC, she emphasized that lowering inflation is a collective duty of both the government and the central bank.

The United Kingdom's inflation rate is expected to be the highest among the Group of Seven developed nations this year and next.

Possible Energy Cost Measures

Reports indicate the government could intervene to lower utility costs, for instance by cutting the present 5% rate of value-added tax charged on energy supplies.

Another possibility is to reduce some of the policy costs presently included in household expenses.

Budgetary Constraints and Expert Expectations

The administration will obtain the latest assessment from the official forecaster, the Office for Budget Responsibility, on Monday, which will clarify how much room there is for these measures.

The consensus from most economists is that the Chancellor will have to declare tax increases or budget cuts in order to adhere to her voluntary debt limits.

Previously on the same day, analysis showed there was a twenty-two billion pound deficit for the Treasury chief to resolve, which is at the lower end of expectations.

"There's a shared responsibility between the central bank and the government to continue tackling some of the sources of inflation," Reeves told reporters in Washington, at the conferences of the IMF and World Bank.

Tax Pledges and International Concerns

While a great deal of the focus has been on likely tax increases, the Treasury chief said the latest figures from the fiscal watchdog had not changed her vow to manifesto promises not to increase rates on earnings tax, sales tax or social security contributions.

She blamed an "unpredictable world" with growing geopolitical and trade concerns for the Budget revenue measures, likely to be targeted on those "with the broadest shoulders."

International Economic Tensions

Commenting on apprehensions about the UK's commercial links with China she said: "Our national security invariably are paramount."

Last week's announcement by Chinese authorities to increase trade restrictions on critical minerals and other materials that are key for advanced tech production led US President Donald Trump to threaten an further 100% tariff on imports from China, increasing the risk of an all-out trade war between the two largest economies.

The US Treasury Secretary called the Chinese action "economic coercion" and "a international production control attempt."

Inquired about accepting the US offer to participate in its conflict with China, the Chancellor said she was "deeply worried" by Chinese actions and urged the Chinese government "not to put up barriers and limit trade."

She said the move was "damaging for the international commerce and generates further obstacles."

"In my view there are areas where we should address Chinese policies, but there are also significant opportunities to export to China's economy, including banking sector and other areas of the economy. We've got to get that balance right."

The chancellor also confirmed she was cooperating with international partners "regarding our own essential resources approach, so that we are less reliant."

NHS Medicine Costs and Funding

The Chancellor also acknowledged that the cost the National Health Service spends on medicines could increase as a consequence of ongoing negotiations with the US government and its pharmaceutical firms, in return for lower tariffs and funding.

A number of the biggest global drug companies have said in recent statements that they are either delaying or scrapping projects in the United Kingdom, with some blaming the modest returns they are receiving.

Recently, the government science advisor said the price the NHS pays for drugs would need to go up to halt firms and drug research funding leaving the UK.

The Chancellor told media: "It has been observed due to the cost structure, that drug testing, innovative medicines have not been offered in the United Kingdom in the extent that they are in other European countries."

"The objective is to guarantee that people receiving treatment from the NHS are able to receive the finest life-saving drugs in the globe. And so we are reviewing these issues, and... looking to obtain additional investment into Britain."